Tekmira Pharmaceuticals Corp (TKMR) 21.45 $TKMR
Tekmira to Present at RBC Capital Markets' Healthcare Conference
GlobeNewswire - Thu Feb 12, 4:07PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a company overview at the 2015 RBC Capital Markets' Healthcare Conference on Tuesday, February 24, 2015 at 12:05 - 12:30 pm (PT) / 3:05 pm - 3:30 pm (ET) at The New York Palace Hotel in New York.
TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 21.45 (-0.22)
Tekmira Announces Filing of Definitive Proxy Statement and Voluntary Delisting From the TSX
GlobeNewswire - Wed Feb 04, 3:36PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and the Canadian SEDAR filing system, regarding the Agreement and Plan of Merger and Reorganization ("the Merger Agreement"
with OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection. This transaction is expected to bring together the companies' broad expertise in antiviral drug discovery and development, Tekmira's Phase I TKM-HBV RNAi therapeutic and OnCore's multiple HBV therapeutic programs, to build a robust portfolio of compounds aimed at eradicating HBV. The merger will create a new global HBV company focused on developing a curative regimen for chronically infected hepatitis B patients by combining multiple therapeutic agents.
TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Tekmira: Bad Idea Genes
Nehulay Risk - at Seeking Alpha - Mon Feb 02, 3:00PM CST
TKMR: 21.45 (-0.22)
Tekmira Pharmaceuticals: Spinning Its Next 'Big Story'
The Street Sweeper - Seeking Alpha - Thu Jan 22, 1:57PM CST
By Sonya Colberg, TheStreetSweeper Senior Investigative Reporter Tekmira Pharmaceuticals ( TKMR ) may not have found its next big biotech thing, after all. After a crazy-good run riding the Ebola scare from obscurity to prominence in just a few...
TKMR: 21.45 (-0.22)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Tekmira Initiates Phase I Clinical Trial of TKM-HBV
GlobeNewswire - Wed Jan 21, 7:38AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has dosed the first subject in a Phase I clinical trial of TKM-HBV, a therapeutic agent designed to reduce hepatitis B surface antigen in patients chronically infected with hepatitis B virus (HBV).
TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:50AM CST
Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
VICL: 1.01 (-0.01), TKMR: 21.45 (-0.22), AMAG: 41.49 (+0.23), GSK: 47.94 (+1.99)
Cooley Advises OnCore Biopharma in Planned Merger With Tekmira Pharmaceuticals
Marketwired - Wed Jan 14, 3:36PM CST
Cooley is advising OnCore Biopharma, Inc. on its proposed merger with Tekmira Pharmaceuticals Corporation to create a new leading global company focused on developing a curative regimen for hepatitis B (HBV) patients by combining multiple therapeutic approaches. Under the terms of the agreement, OnCore will become a wholly-owned subsidiary of Tekmira. Upon closing of the transaction, the stockholders of OnCore will hold approximately fifty percent (50%) of the total number of outstanding shares of capital stock of Tekmira, calculated on a fully-diluted and as-converted basis using the treasury stock method. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million.
TKMR: 21.45 (-0.22)
Tekmira Pharmaceuticals (TKMR) Weak On High Volume
at The Street - Wed Jan 14, 9:01AM CST
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a weak on high relative volume candidate
TKMR: 21.45 (-0.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
XENT: 23.06 (+0.46), CLUB: 6.94 (+0.10), AGEN: 5.03 (-0.01), IMDZ: 25.34 (+1.20), PCYC: 163.28 (+0.23), ADHD: 6.92 (+0.73), TKMR: 21.45 (-0.22), FBSS: 17.59 (-0.11), TKM.TO: 26.51 (-0.73)
Goodyear Tire and KB Home are big market movers
AP - Tue Jan 13, 3:43PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
PCYC: 163.28 (+0.23), IHS: 119.69 (+0.21), OCN: 9.10 (+0.09), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), BMY: 60.04 (+0.56), TIF: 89.05 (+0.95), TKM.TO: 26.51 (-0.73), ELX: 6.57 (+0.22), GT: 25.91 (-0.30), FMI: 48.88 (+0.17), SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), BNCL: 11.54 (-0.02), CVX: 112.78 (+1.92)
Bucking the Trend: New Research on RadioShack, Lululemon, Tekmira, Bristol-Myers and Alcoa
PR Newswire - Tue Jan 13, 6:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including RadioShack (NYSE: RSH), Lululemon (NASDAQ: LULU), Tekmira (NASDAQ: TKMR), Bristol-Myers (NYSE: BMY), and Alcoa (NYSE: AA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AA: 15.81 (+0.16), TKMR: 21.45 (-0.22), BMY: 60.04 (+0.56), RSH: 0.24 (-0.04), LULU: 65.98 (-0.06)
Tekmira Purchases OnCore Biopharma To Find Hep B Cure
at Investor's Business Daily - Mon Jan 12, 12:49PM CST
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become...
TKMR: 21.45 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
Tekmira to Present at RBC Capital Markets' Healthcare Conference
GlobeNewswire - Thu Feb 12, 4:07PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a company overview at the 2015 RBC Capital Markets' Healthcare Conference on Tuesday, February 24, 2015 at 12:05 - 12:30 pm (PT) / 3:05 pm - 3:30 pm (ET) at The New York Palace Hotel in New York.
TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 21.45 (-0.22)
Tekmira Announces Filing of Definitive Proxy Statement and Voluntary Delisting From the TSX
GlobeNewswire - Wed Feb 04, 3:36PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and the Canadian SEDAR filing system, regarding the Agreement and Plan of Merger and Reorganization ("the Merger Agreement"
with OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection. This transaction is expected to bring together the companies' broad expertise in antiviral drug discovery and development, Tekmira's Phase I TKM-HBV RNAi therapeutic and OnCore's multiple HBV therapeutic programs, to build a robust portfolio of compounds aimed at eradicating HBV. The merger will create a new global HBV company focused on developing a curative regimen for chronically infected hepatitis B patients by combining multiple therapeutic agents. TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Tekmira: Bad Idea Genes
Nehulay Risk - at Seeking Alpha - Mon Feb 02, 3:00PM CST
TKMR: 21.45 (-0.22)
Tekmira Pharmaceuticals: Spinning Its Next 'Big Story'
The Street Sweeper - Seeking Alpha - Thu Jan 22, 1:57PM CST
By Sonya Colberg, TheStreetSweeper Senior Investigative Reporter Tekmira Pharmaceuticals ( TKMR ) may not have found its next big biotech thing, after all. After a crazy-good run riding the Ebola scare from obscurity to prominence in just a few...
TKMR: 21.45 (-0.22)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Tekmira Initiates Phase I Clinical Trial of TKM-HBV
GlobeNewswire - Wed Jan 21, 7:38AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has dosed the first subject in a Phase I clinical trial of TKM-HBV, a therapeutic agent designed to reduce hepatitis B surface antigen in patients chronically infected with hepatitis B virus (HBV).
TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 9:50AM CST
Vical announced that it has entered into an agreement with a Japanese biopharmaceutical company, AnGes MG.
VICL: 1.01 (-0.01), TKMR: 21.45 (-0.22), AMAG: 41.49 (+0.23), GSK: 47.94 (+1.99)
Cooley Advises OnCore Biopharma in Planned Merger With Tekmira Pharmaceuticals
Marketwired - Wed Jan 14, 3:36PM CST
Cooley is advising OnCore Biopharma, Inc. on its proposed merger with Tekmira Pharmaceuticals Corporation to create a new leading global company focused on developing a curative regimen for hepatitis B (HBV) patients by combining multiple therapeutic approaches. Under the terms of the agreement, OnCore will become a wholly-owned subsidiary of Tekmira. Upon closing of the transaction, the stockholders of OnCore will hold approximately fifty percent (50%) of the total number of outstanding shares of capital stock of Tekmira, calculated on a fully-diluted and as-converted basis using the treasury stock method. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million.
TKMR: 21.45 (-0.22)
Tekmira Pharmaceuticals (TKMR) Weak On High Volume
at The Street - Wed Jan 14, 9:01AM CST
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a weak on high relative volume candidate
TKMR: 21.45 (-0.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 13, 5:15PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
XENT: 23.06 (+0.46), CLUB: 6.94 (+0.10), AGEN: 5.03 (-0.01), IMDZ: 25.34 (+1.20), PCYC: 163.28 (+0.23), ADHD: 6.92 (+0.73), TKMR: 21.45 (-0.22), FBSS: 17.59 (-0.11), TKM.TO: 26.51 (-0.73)
Goodyear Tire and KB Home are big market movers
AP - Tue Jan 13, 3:43PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
PCYC: 163.28 (+0.23), IHS: 119.69 (+0.21), OCN: 9.10 (+0.09), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), BMY: 60.04 (+0.56), TIF: 89.05 (+0.95), TKM.TO: 26.51 (-0.73), ELX: 6.57 (+0.22), GT: 25.91 (-0.30), FMI: 48.88 (+0.17), SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), BNCL: 11.54 (-0.02), CVX: 112.78 (+1.92)
Bucking the Trend: New Research on RadioShack, Lululemon, Tekmira, Bristol-Myers and Alcoa
PR Newswire - Tue Jan 13, 6:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including RadioShack (NYSE: RSH), Lululemon (NASDAQ: LULU), Tekmira (NASDAQ: TKMR), Bristol-Myers (NYSE: BMY), and Alcoa (NYSE: AA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AA: 15.81 (+0.16), TKMR: 21.45 (-0.22), BMY: 60.04 (+0.56), RSH: 0.24 (-0.04), LULU: 65.98 (-0.06)
Tekmira Purchases OnCore Biopharma To Find Hep B Cure
at Investor's Business Daily - Mon Jan 12, 12:49PM CST
Tekmira Pharmaceuticals (TKMR) stock soared on Monday after the Canadian drugmaker said Sunday that it would buy privately held OnCore Biopharma to bolster its efforts to develop a cure for hepatitis B. The merged company has the potential to become...
TKMR: 21.45 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
